Report Overview

The EU Multi myeloma Therapeutic market was worth USD 1.98 bilion in 2019 and estimated to be growing at a CAGR of XX% to reach USD XX billion by 2028

Multiple myeloma is a rare form of cancer that has a direct impact on the blood in the human body. Because of blood disorders, there has been a huge emphasis on the development of drugs associated with the treatment of the disease. The increasing investment in the R&D of products by large-scale companies across the world will bode well for the market in recent years. Advances in ongoing clinical trials associated with the treatment of the disease will open a huge potential for the companies operating in the market. Regionally, France is the largest market for Multiple Myeloma drug market in the EU, while Italy and Spain are estimated to grow at the highest



Market Growth Drivers

Significant developments in the healthcare sector, along with the increasing prevalence of hematological cancer, are one of the key factors driving the growth of the market. Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves drugs that modulate the immune system and aid in enhancing the efficiency of chemotherapies, radiation therapies, stem cell transplants, and platelet transfusion. Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the body's immune system to identify and attack the myeloma cells, is also providing a boost to the market growth. Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor